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Interferon V Regulates Platelet Endothelial Cell Adhesion 
Molecule 1 Expression and Neutrophil Infiltration into 
Herpes Simplex Virus-infected Mouse Corneas 
By Qizhi Tang* and Robert L. Hendricks*r 
From the Departments of*Microbiology and Immunology *Ophthalmology and Visual Sciences, 
and ~ Pathology, University of Illinois at Chicago, Chicago, Illinois 60612 
Summary 
In a mouse model of herpes implex virus (HSV) 1 corneal infection, tissue destruction results 
from a CD4 + T cell-mediated chronic inflammation, in which interleukin 2 and interferon 
(IFN)~/are requisite inflanunatory mediators andpolymorphonuclear leukocytes (PMN) are the 
predominant infiltrating cells. In vivo neutralization of IFN-y reheved inflammation at least in 
part through a specific block of PMN extravasation into HSV-l-infected corneas. Intercellular 
adhesion molecule (ICAM) 1 and platelet endothelial cell adhesion molecule (PECAM) 1 were 
upregulated on the vascular endothelium of inflamed corneas. Reduced PMN extravasation in 
anti-IFN-',/-treated mice was associated with a dramatic reduction of PECAM-1 but not 
ICAM-1 expression on vascular endothelium. PMN accumulated in the lumen of corneal ves- 
sels after in vivo IFN-~/neutralization. PECAM-1 was readily detectable on PMN inside the 
vessels but was not detectable on PMN that extravasated into the infected cornea. Moreover, 
flow cytometric analysis revealed reduced PECAM-1 expression but elevated major histocom- 
patibility complex class I expression on PMN that recently extravasated into the peritoneal cav- 
ity when compared with PMN in the peripheral blood. We conclude that IFN-y contributes 
to HSV-l- induced corneal inflammation by facilitating PMN infiltration; this appears to be ac- 
complished through upregulation of PECAM-1 expression on the vascular endothelium; and 
PMN downregulate PECAM-1 expression during the process of extravasation. 
I n infectious diseases, inflammation can contribute to the elimination or control of the infectious agent. However, 
in some cases, inflammation can become chronic and result 
in the destruction of healthy tissue. In general, these 
chronic inflammatory esponses are immunologically medi- 
ated. In our mouse model of HSV-1 corneal disease, pri- 
mary infection is followed by the appearance within 2 d of 
epithelial lesions that heal by 4 d after infection. The lesions 
are characterized by the presence of replicating virus in the 
corneal epithelium (1). Resolution of the epithelial lesions 
is followed by a clinically quiescent period of ~1 wk. At 
that time, ~50% of the infected corneas develop a chronic 
inflammation that results in progressive destruction of the 
corneal architecture. It is this chronic inflammation i  the 
corneal stroma that is associated with visual morbidity in 
human patients uffering from HSV keratitis. 
The corneal stromal inflammation resulting from infec- 
tion of mice with the RE strain of HSV-1 is characterized 
by an inflammatory infiltrate comprised predominantly of 
PMN and CD4 + T lymphocytes. This inflammatory re- 
sponse is abrogated by in vivo depletion ofCD4 + T lympho- 
cytes (2). The Thl  cytokines IL-2, IFN-~/, and TNF-od[~, 
but not Th2 cytokines IL-4 and IL-10, are detected in leu- 
kocytes extracted from inflamed corneas after HSV-1 in- 
fection (3). Moreover, studies from our laboratory demon- 
strated that neutralizing the Thl  cytokines IL-2 or IFN-% 
but not the Th2 cytokine IL-4, can prevent he inflamma- 
tion from developing (4). Although Th2 cytokines have 
not been detected in HSV-l-infected corneas, they may 
play a protective role when given exogenously. For in- 
stance, a recent study demonstrated that combined intra- 
corneal and systemic injection of IL-10 before HSV-1 infec- 
tion significantly suppressed corneal inflammation (5). 
These findings suggest that a Thl  CD4 § T lymphocyte re- 
sponse to HSV-1 antigens in the infected cornea regulates 
the infiltration and/or tissue-destructive functions of PMN. 
IFN-'y possesses a number ofproinflammatory character- 
istics. These include upregulation of MHC expression, 
activation of cytokine secretion, phagocytosis, and produc- 
tion of reactive oxygen and nitrogen intermediates by mac- 
rophages (for reviews see references 6-8). In our mouse 
model of HSV-1 corneal infection, the inflammatory infil- 
trate during active disease consists largely of T cells and 
PMN. Macrophages infiltrate the cornea late in the inflam- 
matory process, and thus appear to be primarily involved in 
the resolution of the inflammatory response. Therefore, 
proinflammatory functions of IFN-~ that are mediated 
through macrophages may not contribute substantially to 
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the tissue destruction associated with this disease. I FN-y  
has also been shown to activate PMN and vascular endo-  
thelial cells (9-16). The effects o f l FN- 'y  on vascular endo-  
thel ium include increased expression of  adhesion molecules 
that contribute to PMN extravasation. However,  most of 
the proinf lammatory functions of  I FN-y  were established 
in vitro and require confirmation in clinically relevant 
models of  inf lammation i  vivo. 
In our mouse model of  HSV- l - induced  corneal inflam- 
mation, T cells are not required to control HSV- t  replica- 
tion in the cornea, and in fact contribute to corneal tissue 
destruction and visual morbidity. Thus, this model  offers an 
opportunity to manipulate T cel l -mediated inf lammation 
without the complication of  pathologic changes resulting 
from uncontrol led virus replication. In this study, we have 
used this model  to investigate the proinf lammatory func- 
tions of IFN-~/ in  vivo. 
Materials and Methods 
Ocular HSV-I  Infection and Evaluation of Corneal Inflammation. 
The RE strain of HSV-1 was grown in Vero cells, and intact vir- 
ions were purified on Percoll (Phannacia Biotech Inc. Piscat- 
away, NJ) as previously described (17). Female A/J mice (Freder- 
ick Cancer Research and Development Center, Frederick, MD) 
6-8 wk of age were anesthetized by intramuscular injection of 2 
nag of ketarnine hydrochloride (Phoenix Scientific, Inc., St. Jo- 
seph, MO) and 0.04 nag of acepromazine maleate (Aveco Co., 
Fort Dodge, IA) in 0.1 ml of HBSS. Corneas of anesthetized 
mice were scarified 10 times in a crisscross fashion with a sterile 
30-gauge needle, and the eyes were infected topically with 3 I, zl of 
RPMI containing 105 plaque-forming units of HSV-I. Mice were 
treated with gentalnicin (Genoptic; Allergen America, Puerto 
Rico) topically from day 4 to day 11 after infection to prevent 
bacterial superinfection. 
Corneal stromal opacity resulting from inflammatory cell infil- 
tration was evaluated by daily slit-lamp examination after infec- 
tion as previously described (1, 2). The opacity was scored by an 
observer who was unaware of the treatment given using the fol- 
lowing scale: 1+ = mild haziness; 2+ = moderate opacity not 
obscuring the view of the iris; 3+ = severe opacity in which iris 
details are no longer visible; 4+ = corneal perforation. 
Antibodies and Cytokines. A rat anti-mouse IFN-'y mAb (R4- 
6A2; American Type Culture Collection, Rockville, MD) was 
used for in vivo neutralization. In some experiments, a rat anti- 
HLA-DR5 mAb (SFR3-DR.5; American Type Culture Collec- 
tion) was used as an antibody control, and a rat anti-IL-2 m_Ab 
($4B6; American Type Culture Collection) was used as a speci- 
ficity control. The anti-HLA-DR5 mAb does not bind detect- 
ably to any mouse tissue. All three antibodies were purified from 
hybridoma culture supernatant by affinity chromatography on 
protein G-Sepharose Fastflow (Pharmacia Biotech) and quanti- 
fied with a radial immunodiffusion kit (ICN Biomedicals; Costa 
Mesa, CA). For immunohistochemistry, anti-intercellular dhe- 
sion molecule (ICAM) I 1 (YN/17.4), anti-Mac-1 (M1/70), and 
anti-LFA-1 (M17/4.2) mAbs, all obtained from American Type 
lAbbreviations u ed in this paper: H&E, helnatoxylin and eosin; HUVEC, 
human umbilical vein endothelial cells; ICAM, intercellular adhesion 
molecule; PECAM, platelet endothelial cell adhesion molecule. 
Culture Collection, were purified from hybridoma culture me- 
dium and biotinylated using an immunoprobe biotinylation kit 
(Sigma Chemical Co., St. Louis, MO). The biotinylated anti- 
mouse platelet endothelial cell adhesion molecule (PECAM) 1 n~b 
(MEC 13.3) and anti-CD3 (145-2Cll) were purchased from 
PharMingen (San Diego, CA). Anti-mouse granulocyte mAb 
(RB6-8C5, provided by R. Coffman, DNAX Research Institute, 
Palo Alto, CA) was isolated from hybridoma culture medium and 
conjugated to FITC using standard procedures. A rat mAb spe- 
cific for a nonpolymorphic region of mouse MHC class I (M1/ 
42.3.9.8) was obtained from American Type Culture Collection, 
purified from hybridoma supernatant as described above, and 
used in conjunction with a FITC-conjugated goat anti-rat IgG 
(H + L) (Jackson hnmunoResearch Laboratories, Inc., West Grove, 
PA) in an indirect staining procedure. Mouse rIFN-y was pur- 
chased from Genzyme Corp. (Cambridge, MA). 
Histologic and Immunohistologic Examination. Inflamed eyes were 
excised at different imes after mAb treatment, fixed in 10% neutral 
buffered formalin, and 5-~xm paraffin sections were prepared. The 
sections were stained with hematoxylin and eosin (H&E), mounted 
with Permount, and coverslipped for microscopic examination. 
For immunohistochemical st ining, eyes were embedded in OCT 
compound (Optimal Cryogenic Temperature; Miles, Inc., Elk- 
hart, IN), snap-frozen immediately in an isopentane-dry ice bath, 
and 6-bLm sections were cut at -20~ Sections were fixed with 
acetone for 10 rain and blocked with PBS-BGEN (3% BSA, 
0.25% gelatin, 5 mM EDTA, 0.025% NP-40) for 20 min, and 
then processed for immunofluorescence or immunoperoxidase 
staining. For inununoperoxidase staining, sections were incubated 
with biotinylated antibodies for I h at 37~ Cells with bound 
antibodies were identified with a peroxidase reagent (Elite 
Vectastain ABC; Vector Laboratories Inc., Burlingame, CA) us- 
ing a diaminobenzidine p roxidase substrate kit (Vector Labora- 
tories, Inc.). For two-color immunofluorescence staining, sections 
were then incubated for I h with a lmxture of 0.5 I.tg/nd of FITC- 
labeled anti-mouse granulocyte mAb (RB6-8C5) and 4 ~g/ml of 
biotinylated anti-mouse PECAM-1. The sections were then 
washed and incubated with 0.6 b~g/ml of PE-conjugated strepta- 
vidin (PharMingen) for 30 min. Slides were then washed, 
mounted with Pemlafluor (Lipshaw, Detroit, MI), and coverslipped. 
Evaluation of Staining Intensity. The intensity of staining of 
PECAM-1 on the vascular endothelium was analyzed with an 
image processing system (Zeiss SEM-IPS; Carl Zeiss, Inc., 
Thornwood, NY) established in Dr. Paul Knepper's laboratory at 
Children's Memorial Hospital (Chicago, IL). The sampling win- 
dow was 0.015 mm 2 and the resolution limit was 0.24 I.~tn. All 
measurements were made with a planapochromatic 40X/1.0 oil 
immersion objective under a light microscope (Carl Zeiss, Inc.). 
They were made as the percentage of transmission with the use of 
a scanning spectrophotometer (Carl Zeiss, Inc.) with the wave- 
length set at 500 + 10 nm. The proper wavelength was deter- 
mined by a system (Zonax; Carl Zeiss, Inc.). Briefly, spectral 
scans were performed using a computer-controlled scanning 
monochromator (Carl Zeiss, Inc.) that scans a spectrum between 
400 and 700 nm in 10-mn increments. The spectral data were 
then corrected for microscope lighting (tungsten lamp), and the 
wavelength was selected at a range slightly off the maximal ad- 
sorption so the dark end of the measurement range would not be 
saturated. A zero transmission value was set with a black back- 
ground. A 100% transmission value was measured as the average 
value of an empty field. Four corneas from each treatment group 
were excised, and frozen sections were stained together for PE- 
CAM-1 as described above. The staining intensity of the corneal 
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blood vessels in each section was measured in a masked fashion. 
The data were recorded as the average OD per vessel. Using neu- 
tral density filters, the Zonax system was found to provide linear 
readings (R 2 = 0.9989) over a scale of 0.1 to 3 .00D units, which 
exceeded the range of OD readings for our histologic samples. 
The image analysis provided an objective evaluation of staining 
intensity, was in good general agreement with scores based on vi- 
sual examination, but was able to discriminate differences in stain- 
ing intensity that would be difficult to discern by microscopic ex- 
amination alone. 
PMN Isolation. PMN were isolated from the peripheral blood 
by centrifugation a Percoll gradient using a slight modification 
of a previously described technique (18). Briefly, blood was col- 
lected from the axillary plexus into tubes containing EDTA, 
diluted with an equal volume of 2X HBSS, and incubated for 
15 man at room temperature. The cells were layered over 80%1.5X 
hypertonic Percoll (Cell/Flex-l124; Atlanta Biologicals, Inc., Nor- 
cross, GA) and centrifuged at 1200 g for 30 rain at 20~ Cells 
from the Percoll-medium interface were washed with 1X HBSS, 
and residual RBC were lysed with Tris-NH4C1. A thioglycolate- 
induced peritoneal exudate was used as a source of recently ex- 
travasated PMN. Mice received an intraperitoneal injection of 1 ml 
of thioglycolate. 3 h later, the peritoneal exudate was removed, 
washed once in RPMI 1640 medium supplemented with 5% 
FCS, and then incubated on a plastic surface for 1 h at 37~ in 
the same medium. The nonadherent cells were removed and 
shown to be >98% PMN based on nuclear morphology. 
Flow Cytometric Analysis of Adhesion Molecule Expression on PMN. 
Levels of PECAM-1 or MHC class I on PMN obtained from the 
peripheral blood or a thioglycolate-induced p ritoneal exudate 
was assessed by flow cytometry (Coulter EPICS V; Coulter 
Corp., Hialeah, FL). The enriched PMN (0.5-1 • 106) were 
added to the U-bottom wells of a 96-well plate and treated with 
Fc Block (0.5 p~g/10 r cells of anti-CD32/CD16; PharMingen, 
San Diego, CA) for 10 rain on ice. The cells were then treated 
with biotinylated mAb to PECAM-1 (2 p,g/106 cells) or with a 
similar concentration fa biotinylated rat mAb of irrelevant spec- 
ificity and incubated on ice for 30 min. The cells were washed 
and exposed to 100 bd of 5 lag/ml strepavidin-PE (PharMingen) 
for 30 rain. Alternatively, after treatment with Fc Block, the cells 
were exposed to an unconjugated rat mAb specific for mouse 
Figure I. IFN-~/ producing cells in HSV-l-infected corneas. Frozen 
sections were prepared from eyes with 2+ corneal inflammation at day 
12-14 after infection. IFN-~-expressing c ll  in the cornea (arrows) were 
detected by ABC immunoperoxidase staining. • 132. 
MHC class I, followed by FITC-conjugated goat anti-rat Ig. All 
cells were then washed and resuspended in PBS containing 5% 
FCS, 0.1% NAN3, and 130 b~g/ml ofpropidium iodide. 
The flow cytometric analysis of PECAM-1 and MHC class I
expression was restricted to live PMN based on forward angle 
and 90 ~ light scatter, and exclusion of propidium iodide-stained 
cells. A sample of the gated cells was collected, an an H&E- 
stained cytospin preparation was found to be >98% PMN based 
on morphology. 
Results  
Role of lFN- y in the Maintenance and Progression of Corneal 
Inflammation. Previous studies involving in vivo neutral- 
ization of IFN-~/before HSV-1 corneal infection demon- 
strated a requirement for IFN-y in the initiation of the in- 
flammatory response (4). However, the involvement of 
IFN-y in the progression of corneal inflammation was not 
assessed. To clarify this issue, we performed experiments in
which in vivo neutralization of IFN-y was initiated when 
mice reached the 1+, 2+,  or 3+ level of corneal inflam- 
mation. In our model, 50-60% of infected corneas devel- 
oped 1+ to 2+ inflammation from day 10 to 14 after in- 
fection, and reached 3+ or even corneal perforation (4+) 
by day 17-20 after infection. Numerous IFN-~/-producing 
cells were detected in the corneas at all stages of inflamma- 
tion, as illustrated in Fig. 1. 
Neutralization was accomplished by an intraperitoneal 
injection of 0.5 nag of IFN-y-neutral izing mAb, followed 
by a second injection of 0.5 nag of the same mAb 7 d later. 
Preliminary experiments and previously published results 
(2, 4) established that corneal disease, as evaluated clinically 
or histologically, developed in an identical manner when 
control mice received an intraperitoneal injection of rat 
mAb of irrelevant specificity (anti-HLA-DR) or PBS (data 
not shown). Therefore, in these experiments, control mice 
received intraperitoneal injections of PBS. Corneal disease 
was monitored by daily slit-lamp examination until the dis- 
ease pattern stabilized. The PBS-treated control mice 
showed progression of corneal inflammation that is typical 
for our model. When mice were treated with PBS at the 
2+ stage of corneal inflammation (10-14 d after infection), 
all progressed to more severe disease (Fig. 2 A), and 50% of 
the infected corneas of PBS-treated mice became so se- 
verely inflamed that the cornea perforated (4+ disease). 
Similar treatment with ant i - IFN-y resulted in a rapid re- 
versal of corneal inflammation. As early as 2 d after anti-  
IFN-~/treatment, inflammation i some corneas was com- 
pletely resolved (Fig. 2 B). The disease pattern stabilized 12 d 
after the initial treatment, when 55% of the corneas of 
mAb-treated mice improved to normal, 36% remained at a 
nonprogressive 2+ stage, only 9% progressed to the 3+ 
stage of inflammation, and none of the corneas of treated 
mice perforated. 
Initiation of anti - IFN-y mAb treatment when mice were 
at the 1+ stage of corneal inflammation resulted in com- 
plete resolution of inflammation in all corneas within 8 d of 
the initial treatment (not shown). Treatment with anti-  
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IFN-y is required for the progression of HSV-l-induced 
corneal inflammation. Groups of 20-22 mice at the 2+ stage of corneal 
inflammation received an intraperitoneal injection of 0.5 ml of PBS (/t) 
or 0.5 mg of IFN-'y-neutralizing mAb (B), and corneal inflammation was 
monitored by slit-lamp examination. A second identical treatment was 
administered 7 later. Data are recorded as the percentage of nfice exhib- 
iting different degrees of" inflammation. Disease progression was sigmifi- 
candy g'reater (P <0.0001) in the PBS-treated controls than in the anti- 
IFN-y-treated mice as assessed byFisher's exact est. 
I FN-y  mAb that was initiated at the 3+ stage of  corneal 
inflammation did not result in an apparent improvement in
the clinical condition of the corneas. It is noteworthy, 
however, that even in the latter group, none of the mice 
progressed to corneal perforation, and histologically the in- 
flammation appeared to be resolving (not shown). Failure 
of  mAb treatment to improve the clinical condition of  3+ 
corneas was probably due to preexisting, irreversible struc- 
tural damage to the cornea at the time of treatment. These 
results demonstrate that I FN-y  is required during all stages 
of  the progression of  the inflammatory response in HSV-1 -  
infected corneas. 
Role of lFN- T in Leukocyte Extravasation. To investigate the 
mechanisms by which IFN-3' regulates the progression of  
inflammation, we compared histologic changes in corneas 
with 2+ inflammation after intraperitoneal injection of  
ant i - I FN-y  mAb with those in control (ant i -HLA-DR5) 
mAb-treated mice. The cornea is normally avascular, but 
corneal inflammation is accompanied by gradual neovascu- 
larization. During the early stages of  inflammation, the leu- 
kocytes extravasate from blood vessels in the peripheral 
cornea, and then migrate to the central cornea. At the 2+ 
stage of HSV- l - induced corneal inflammation, blood ves- 
sels had begun to invade the corneal stroma, and a dense 
infiltrate consisting of  PMN (Fig. 3 A) and CD3 + T cells 
(Fig. 3 B) was observed in the perivascular space. Within 
48 h after ant i - I FN-y  treatment, a marked reduction of  
PMN infiltration into the perivascular space was observed 
(Fig. 3 C), whereas the density of  CD3 + T cells was not 
noticeably affected (Fig. 3 D). As a specificity control, mice 
received similar treatment with an IL-2-neutralizing mAb. 
The anti- IL-2 treatment did not influence the infiltration 
of  PMN (Fig. 3 E) or CD3 + T cells (Fig. 3 F) into the 
perivascular space. Thus, IFN-~, mediates inflammation in 
HSV- l - in fected corneas, at least in part by regulating 
PMN extravasation from blood vessels in the peripheral 
cornea. 
Modulation of Adhesion Molecule Expression by IFN-T. 
ICAM-1 was not detectable by immunohistochemical 
staining on the vascular endothelium of  normal mouse cor- 
neas, but its expression was markedly upregulated on the 
vascular endothelium of  infected corneas at the 2+ stage of  
inflammation (Fig. 4 A). Because ICAM-1 is essential for 
PMN extravasation i some models (19-22), and its ex- 
pression on vascular endothelial cells can be induced by 
IFN-y  (10-12, 14), we hypothesized that in vivo neutral- 
ization of I FN-y  might have blocked PMN extravasation 
into HSV- l - in fected corneas by reducing ICAM-1 expres- 
sion in the lumen of  corneal vessels. However,  ICAM-1 
expression on the corneal vascular endothelium was not 
noticeably reduced up to 48 h after ant i - IFN-y  treatment 
(Fig. 4 B), a period when PMN infiltration into the 
perivascular space was blocked. Ant i - IFN-~/treatment also 
failed to alter the expression of  Mac-1 and LFA-1, the leu- 
kocyte counterreceptors for ICAM-1 on the small number 
of  leukocytes that did infiltrate the corneas of  ant i - I FN-  
y-treated mice (data not shown). The failure of ant i - IFN-y 
treatment to alter the expression of  these adhesion mole- 
cules suggests either that I FN-y  is not necessary for regulat- 
ing their expression in our model or that a slow turnover 
rate of  these molecules on vascular endothelial cells and 
leukocytes precluded detection in the time frame of  our 
experiments. In either case, it would appear that anti- IFN-'y 
treatment does not block PMN extravasation through 
modulation of  ICAM-1 expression on corneal vascular en- 
dothelium in our model. 
Recent studies have established a role for PECAM-1 in 
PMN extravasation i  vitro and in vivo (23-25). PECAM-1 
is expressed constitutively at low levels on peripheral blood 
vessels in normal mouse corneas (not shown), and its ex- 
pression was strongly upregulated in infected corneas with 
2+ inflammation (Fig. 5, A and B). Within 24 h after anti -  
I FN-y  treatment of  mice with 2+ corneal inflammation, 
PECAM-1 expression on corneal vascular endothelium was 
noticeably reduced (not shown). By 48 h after treatment, 
PECAM- I  expression was reduced to a level that is consti- 
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Figure 3. Representative photomicrographs illustrating the effect of IFN-y neutralization on leukocyte infiltration into HSV-l-infected corneas. 
H SV-l-infected mice exhibiting the 2+ level of corneal inflammation received an intraperitoneal injection of PBS, an IFN-3t-neutralizing rat mAb, or 
an IL-2-neutralizing rat mAb, and 48 h later corneas were examined histologically. H&E stained paraffin sections of corneas from PBS-treated mice (A) 
and anti-IL-2-treated mice (C) showed a heavy PMN infiltration into the perivascular space, which was markedly reduced in anti-IFN-~/-treated mice 
(E). In contrast, immunohistochemical staining revealed similar numbers of CD3 + T cells in corneas from PBS-treated (B), anti-IL-2-treated (D), and 
anti-lFN-y-treated mice (F). X 132. 
tutively expressed in normal corneas (Fig. 5, C and D). The  
reduct ion o f  PECAM-1  expression correlated temporal ly 
with the inhibit ion o fPMN extravasation i the corneas. 
To  quantitatively assess the effect o f  IFN-~/ neutraliza- 
t ion on PECAM-1  expression on the corneal vascular en- 
dothel ium, HSV- l - in fec ted  mice with 2+ corneal inflam- 
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mation received an intraperitoneal injection o f  ant i - IFN-~/ 
mAb or a control  rat mAb (ant i -HLA-DR5) .  2 d later, 
corneas from the two treatment groups, or f rom normal 
(noninfected mice) were removed,  and frozen sections 
were stained simultaneously and under identical condit ions 
for PECAM-1 .  In masked studies, the level o f  PECAM-1  
expression on vascular endothe l ium was assessed by image 
analysis as descr ibed in Materials and Methods .  The  data 
obta ined f rom scans of  40 sections of  vessels in infected 
corneas of  ant i - I FN-y - t reated  mice, 42 vessels in infected 
corneas of  contro l  mAb-- t reated mice, and 17 vessels in 
normal  corneas are recorded in Fig. 6 as the average stain- 
ing intensity (OD)  o f  each vessel. By 48 h after ant i - I FN-y  
treatment,  PECAM-1  expression on the vascular endothe-  
l ium was significantly reduced (P <0.001)  when compared  
wi th  PECAM-1  expression on  vessels o f  PBS-t reated con-  
trols. The  level o f  PECAM-1  expression on  vascular en-  
Figure 4. Representative photomicrographs illustrating the effect of 
IFN-y neutralization on vascular endothelial expression of ICAM-1 in 
HSV-l-infected corneas. HSV-l-infected mice exhibiting the 2+ level 
of corneal inflammation received an intraperitoneal injection of PBS (A) 
or anti-IFN-"/ (B), and 48 h later corneas were examined for ICAM-I 
expression by imnmnohistochemistry. T eatment did not markedly influ- 
ence ICAM-1 expression. •
Figure 5. Representative photomicrographs illustrating the effect oflFN-y neutralization  PECAM-1 expression on vascular endothdium of HSV- 
1-infected corneas. HSV-l-infected mice exhibiting the 2+ level of corneal inflammation received an intraperitoneal injection of control mAb (anti- 
HLA-I)FZ5) or anti-lFN-y, and PECAM-1 expression was evaluated by immunohistochemistry. PECAM-1 expression remained high 48 h after control 
mAb treatment (A and B) but was markedly reduced 48 h after anti-IFN-y treatment (C and D). Depicted are vessels with the highest (A) and average 
(B) PECAM-1 expression i  controls, and the average (C) and lowest (D) PECAM-1 expression i  anti-IFN-y-treated mice. The average staining iuten- 
sity of these vessels, as assessed by image analysis, was 0.44 (A), 0.25 (B), 0.12 (C), and 0.02 (D). These fields were chosen to represent the range of stain- 
ing intensities hown in Fig. 6. Note the accumulation ofPMN (arrozvheads) in the lumen of vessels with low PECAM-1 expression. •
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Figure 6. IFN-y neutralization reduces PECAM-1 expression on the 
vascular endothelium of HSV-l-infected corneas (open symbols) to ap- 
proximately that of normal corneas (solid symbols). HSV-l-infected mice 
exhibiting the 2+ level of corneal inflammation received an intraperito- 
neal injection of  control mAb (anti-HLA-D1K5) or anti-IFN-y, and in- 
fected and normal corneas were excised 48 h later. Frozen sections of cor- 
neas from four mice per group were examined for PECAM-1 expression 
by ABC immunoperoxidase staining. The level of PECAM-1 expression 
was assessed in a masked fashion by image analysis as described in Materi- 
als and Methods, and recorded as the mean staining intensity (OD) per 
corneal vessel. The mean level of PECAM-1 expression i  each group is 
indicated by a solid line. The data were analyzed by a one-way analysis of 
variance followed by Tukey's posttest. PECAM-1 expression was signifi- 
cantly elevated in the control mAb group (P <0.001) but not in the anti- 
IFN-y-treated group (P >0.05) when compared with normal corneas. 
PECAM-1 expression was significantly ower (P <0.001) in anti-IFN- 
y-treated mice than in control mAb-treated mice. 
dothelium of infected corneas 48 h after ant i - IFN-y treat- 
ment was not significantly different (P >0.05) from that 
constitutively expressed on vascular endothelium of normal 
corneas. The magnitude of the difference in staining inten- 
sity in treated and control corneas, as assessed by image 
analysis, can be visualized in Fig. 5. The staining intensity 
of vessels in Fig. 5, A-D, were 0.48, 0.25, 0.12, and 0.02, 
respectively. This result is consistent with the hypothesis 
that IFN-y is required for maintaining a high level of  
PECAM-1 expression on the vascular endothelium of HSV- 
1-infected corneas, and that a high level of  PECAM-1 ex- 
pression is required for PMN extravasation. 
We noted that the level of  PECAM-1 expression was 
quite consistent in vessels of a given cornea, and very con- 
sistent on the same vessel in serial sections. It was possible, 
therefore, to evaluate PMN extravasation i serial sections 
adjacent o those that exhibited high (0 .2 -0 .40D)  and low 
(0 -0 .20D)  expression of PECAM-1 on corneal vessels. 
Sections were simultaneously stained for PECAM-1 and 
PMN using a two-color immunofluorescent stain. As illus- 
trated in Fig. 7, vessels that expressed a high concentration 
of  PECAM-1 showed a heavy density of  PMN in the 
perivascular space. In contrast, those vessels exhibiting 
barely detectable PECAM-1 showed no evidence of PMN 
extravasation. 
The photomicrographs in Figs. 5 D and 7 illustrate two 
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additional points that are of interest. First, we note that 
PMN tend to accumulate in the lumen of  vessels that ex- 
hibit low levels of  PECAM-1 expression. This is consistent 
with our observation that ICAM-1 expression remains high 
in these vessels. Taken in the context of the current para- 
digm of  the adhesion cascade that controls PMN extravasa- 
tion, this observation would suggest hat integrin-mediated 
tethering of  the PMN to the vascular endothelium is not 
altered by IFN-',/ neutralization, but PECAM- l -mediated 
transendothelial migration is blocked. 
PMN in the peripheral blood have been shown to ex- 
press low but detectable levels of  PECAM-1 (26). We 
noted a low level of  PECAM-1 staining on PMN that 
were trapped in the lumen of vessels ofanti- IFN-~/-treated 
mice (Figs. 5 D and 7 E). Interestingly, PMN that extrava- 
sated into the cornea did not express detectable PECAM-1 
(Figs. 5 A and 7 B). This suggested that PECAM-1 expres- 
sion on PMN is dramatically reduced after extravasation. 
However, to clearly establish this point required flow cyto- 
metric analysis. Because it is difficult to extract sufficient 
PMN from the cornea for flow cytometric analysis, we 
chose as an alternative to compare PECAM-1 expression 
on PMN obtained from the peripheral blood of mice with 
PECAM-1 expression on PMN obtained from a thyogly- 
colate-induced peritoneal exudate. Thus, PMN obtained 
from the peripheral blood or peritoneal exudate were 
stained with biotin-conjugated anti -PECAM-1 or an iso- 
type-matched, biotin-conjugated mAb of irrelevant speci- 
ficity, followed by PE-conjugated avidin. As illustrated in 
Fig. 8, PECAM-1 expression was markedly reduced on 
PMN that had recently extravasated into the peritoneal 
cavity (mean fluorescence intensity [channel] = 39.9, mean 
channel difference [compared with control mAb] = 1.3) 
when compared with PMN from the peripheral blood 
(mean fluorescence intensity = 99.6, mean channel differ- 
ence = 54.4). A similar analysis of MHC class I expression 
revealed elevated expression on the peritoneal exudate 
PMN (mean fluorescence intensity = 131.5, mean channel 
difference = 68.1) when compared with those from the 
peripheral blood (mean fluorescence intensity = 110.5, 
mean channel difference = 30.3). The peritoneal exudate 
PMN lacked detectable PECAM-1 expression whether or 
not they were depleted of macrophages (data not shown), 
ruling out the possibility that PECAM-1 was selectively 
lost from peritoneal exudate PMN during the 1-h incuba- 
tion on plastic to remove macrophages. Thus, PECAM-1 
appears to be lost from PMN during extravasation i  a 
manner analogous to L-selectin, whereas MHC class I ex- 
pression is elevated uring this process. 
PECAM-1 is a recently described member of the adhe- 
sion molecule family, and the regulation of  its expression is 
not yet well documented. To confirm our finding that 
IFN-~/ regulates PECAM-1 but not ICAM-1 expression 
on vascular endothelium in vivo, 100 U of  mouse rlFN-~/ 
was injected into normal mouse corneas, and the corneas 
were monitored for PECAM-1 and ICAM-1 expression by 
immunohistochemistry and image analysis. As shown in 
Fig. 9, PECAM-1 was constitutively expressed at a low 
Figure 7. Relationship between PECAM-1 expression on corneal vessels and PMN extravasation. HSV-l-infected mice exhibiting the 2+ level of 
corneal inflammation received an intraperitoneal injection of a ti-IFN-y. After 48 h, two-color immunoituorescence staining of frozen sections of the 
corneas was used to simultaneously identify PECAM-I expression on vascular endothelium (phycoerytherin, red) and PMN (FITC, green). Phase contrast 
shows the location of corneal blood vessels (A and D). The accumulation of PMN in the lumen of vessels of anti-IFN-y-treated corneas tends to obscure 
the vessel walls (arrowheads). Corneas with high PECAM-I expression on the vascular endothelium (/3) exhibited large numbers of PMN in the perivas- 
cular space (C). In contrast, corneas expressing barely detectable levels of PECAM-1 on the vascular endothelium (E) showed very few PMN in the 
perivascular space (F). Note the accumulation of PMN in the lumen of vessels with reduced PECAM-1 expression (F). • 132. 
level on normal corneal vascular endothel ium, and that 
level o f  expression was not significantly altered by intracor- 
neal injection o f  PBS. However ,  PECAM-1  expression 
was strongly upregulated 3 h after injection o f  r lFN- 'v.  In 
contrast, ICAM-1  was not detectable on normal vascular 
endothelial cells, and its expression was not induced at any 
t ime after injection of  r lFN-~/(data not shown). This result 
lends further support to the not ion that PECAM-1  but not 
ICAM-1  expression is regulated by IFN-y  in the inflamed 
cornea after HSV-1 infection. A l though the level of  
PECAM-1  expression induced by r lFN-~/appears to be as 
high as that observed in the inflamed corneas, no infiltrat- 
ing PMN were seen in the r lFN- 'v - in jected corneas at the 
t ime points examined. This suggests PECAM-1  expression 
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Figure 8. PECAM-1 and MHC class I expression profile of mouse PMN freshly isolated from circulating white blood cells (WBC) or ofPMN isolated 
from peritoneal exudate cells (PEC). Cells were stained with biotinylated rat mAb to PECAM-1 or with a biotinytated rat mAb of irrelevant specificity 
followed by PE-conjugated streptavidin; or were stained with rat mAb to a nonpolymorphic region of mouse MHC class I followed by FITC-conjugated 
anti-rat lg. The cells were analyzed on a flow cytometer as d sc ibed in Materials and Methods. PMN that extravasated into the peritoneal cavity resem- 
bled those that extravasated into the cornea in that they expressed lower levels of PECAM-1 but evated levels of MHC class I when compared with 
PMN in the peripheral blood. 
alone is not sufficient for PMN extravasation, which is 
hkely to require orchestrated expression of  several adhesion 
molecules. 
Discussion 
Despite the availability of  effective antiherpetic drugs, 
HSV-1 corneal infections continue to be a major contribu- 
tor to visual morbidity. The ability of  the virus to establish 
a latent infection in the sensory neurons makes eradication 
of  the virus from the infected individual impossible at the 
present time. For this reason, we believe our best current 
hope for improved ophthalmic treatment lies in a better 
understanding of the pathological processes that contribute 
to the corneal destruction associated with HSV infection. 
Toward this end, we have established a mouse model of  
the disease. Using the mouse model, we and others have 
demonstrated that corneal destruction is not a direct effect 
of the virus, but rather is the consequence of  a T lympho- 
cyte response to HSV antigens (2-4, 27-36). Paradoxically, 
a T lymphocyte response also contributes to prevention of  
virus spread to the periocular skin and to the brain (29, 34). 
It becomes imperative, therefore, to understand the imnm- 
nologic mechanisms that may uniquely contribute to the 
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proinflammatory environment within the infected cornea 
and that may be subject o local regulation. 
Previous studies from our laboratory have established 
that the Th l  cytokines IL-2 and IFN-~/are requisite medi- 
ators of  the inflammatory response to HSV-1 in the mouse 
cornea (4). In those studies, corneal inflammation was pre- 
vented by treating mice systemically with mAb to IL-2 or 
IFN-~/. However, a more clinically relevant question may 
be whether these mAb can treat existing inflammation. In 
addition, preventing disease does not offer an opportunity 
to identify mechanisms by which these molecules partici- 
pate in the inflammatory process. In this report, we dem- 
onstrate that mAb to IFN-~/ can be effective in ameliorat- 
ing established HSV- l - induced corneal inflammation. 
Treatment with anti-IFN-~/ mAb had a palliative effect 
when initiated at all stages of  inflammation, suggesting that 
IFN-~ is required both for initiation and for maintenance 
or progression of  the inflammatory process. These findings 
suggest hat appropriate manipulation of  the proinflamma- 
tory functions of  IFN-~/might  provide an effective means 
of  intervening in the inflammatory process. We were thus 
encouraged to pursue studies designed to define the mech- 
anisms by which IFN-~/regulates inflammation in HSV-1 -  
infected mouse corneas. 
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Figure 9. Induction of PECAM-1 expression on corneal vascular en- 
dothelium after intrastromal injection ofrlFN-T into normal mouse cor- 
neas. Mouse rIFN-~/(100 U in 0.5p.1 ofPBS [A]) or 0.5 p.1 of PBS alone 
(A) was injected into normal ouse corneas. At the indicated time after 
injection, frozen sections of corneas from four mice per group were ex- 
amined for PECAM-1 expression by ABC immunoperoxidase staining. 
The level of PECAM-1 expression was assessed in a masked fashion by 
image analysis as described in Materials and Methods and recorded as the 
mean staining intensity (OD) per corneal vessel. The mean level of 
PECAM-1 expression vessels in injected corneas is indicated by a solid 
line; the mean level of PECAM-1 expression on vessels ofnornlal corneas 
is indicated by the dotted line. Data from all three groups were analyzed 
by a one-way analysis of variance followed by Tukey's multiple compari- 
son test. The P values are for a comparison of the PECAM-1 expression 
in PBS and rIFN-T-injected corneas. PECAM-1 expression in PBS- 
treated corneas did not differ significantly from that in normal corneas at 
any time (P >0.05). PECAM-1 expression in the rlFN-'y-injected cor- 
neas was significantly (P <0.001) higher than that in normal corneas at 
3 h but was not significantly different (P >0.05) at 1 or 24 h. 
Our  histologic studies have provided some important 
clues to how IFN-~/regulates inflammation in the cornea. 
Within 48 h after treatment with mAb to IFN-% a marked 
reduction in the number of  PMN in the perivascular space 
of  the peripheral cornea was noted. The specificity of  this 
effect was emphasized by the fact that similar treatment with 
mAb specific for IL-2, while also reducing inflammation in 
the HSV- l - infected cornea (Tang, Q., W. Chen, and R.L. 
Hendricks, manuscript submitted for publication), did not 
block PMN extravasation (Fig. 3). These observations 
demonstrated a role for IFN-~/ in regulating PMN extrava- 
sation into infected corneas. In contrast, the continued 
presence of  T lymphocytes in the perivascular space of  the 
cornea after treatment with mAb to IFN-~/suggests either 
that IFN-'y does not regulate T lymphocyte xtravasation 
or that the T lymphocytes that were present in the perivas- 
cular space of  treated mice had extravasated before treat- 
ment but failed to migrate out of  the perivascular region. 
Previous investigations established that IFN-3~ treatment 
differentially increases adhesion of  T cells, but not PMN,  
to cultured endothelial cells (37). In addition, intradermal 
injection of  IFN-~ induces infiltration of  T cells and 
monocytes, but not PMN (38, 39). Taken together with 
our current findings, these results suggest hat (a) I FN-y  is 
necessary, hut perhaps not sufficient, for PMN extravasa- 
tion; and (b) IFN-~/is sufficient, but may not be necessary, 
for T cell extravasation. In the latter case, other inflamma- 
tory cytokines that are present in the milieu of  the inflamed 
cornea may supplant he role of  IFN-'y in T lymphocyte 
extravasation. 
Treatment with anti-IFN-~/ could regulate PMN ex- 
travasation by altering the pattern of  adhesion molecule 
expression on the vascular endothelium. ICAM-1 and 
PECAM-1 are Ig superfamily adhesion molecules that have 
been shown to participate in the interaction of PMN with 
the vascular endothelium. ICAM-1 expression on the vas- 
cular endothehum is regulated by a variety of  proinflam- 
matory mediators including IFN-~/ (10, 11, 40-43). The 
importance of  [CAM-1 for PMN extravasation at inflam- 
matory sites appears to vary when tested in different models 
of  acute inflammation (19-22, 44-47). Although we ob- 
served increased expression of  ICAM-1 on the corneal vas- 
cular endothelium after HSV-1 infection, its expression 
was not altered by ant i - IFN-~/treatment during the period 
that inhibition of  PMN extravasation was noted. Our  re- 
sults do not imply a lack of  ICAM-1 involvement in PMN 
extravasation i  this model, but only that inhibition of  
PMN extravasation i to HSV- l - in fected corneas of  anti -  
IFN-~ treated mice was not effected through modulation 
of  ICAM-1 expression. This result might be expected be- 
cause several cytokines, including TNF-ot and IL-1, that 
are capable of inducing ICAM-1 expression on vascular 
endothelium have been shown to be produced in HSV-1 -  
infected corneas (3, 48). 
PECAM- I  is constitutively expressed on vascular endo- 
thelium and concentrated in the endothelial junctions (23). 
IFN-~/regulation of  PECAM-1 expression on human um- 
bilical vein endothelial cells (HUVEC) has been studied 
in vitro. One study (49) revealed a moderate increase in 
PECAM-1 expression on HUVEC after exposure to IFN-% 
However, a more recent study (50) demonstrated that 
IFN-~/ did not change PECAM-1 transcription or total 
surface expression on HUVEC,  but did induce a redistri- 
bution of  PECAM-1 away from intracellular junctions. 
The reason for the difference in PECAM-1 regulation in 
the two studies is not clear, but may relate to the condition 
of  the HUVEC at the time of  assay. For instance, low con- 
stitutive expression of  PECAM-1 on HUVEC may be up- 
regulated by IFN-',/, whereas high constitutive expression 
may be unaffected. 
To our knowledge, our study is the first to examine 
IFN-'y regulation of  PECAM-1 expression on vascular en- 
dothelium in vivo. We observed a rather dramatic upregu- 
lation of PECAM-1 expression when IFN-~ was injected 
into a normal cornea, and an equally dramatic downregula- 
tion when IFN-~ was neutralized in an inflamed cornea. 
The kinetics of  the two reactions was quite similar. 
PECAM-1 expression in the cornea was significantly in- 
creased 3 h after injection of  IFN-% and then returned to 
baseline levels by 24 h. Similarly, reduction of  PECAM-1 
expression in inflamed corneas became apparent 24 h after 
treatment with anti- IFN-"/ mAb, with the maximal effect 
seen at 48 h. The seemingly more dramatic regulatory el- 
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fect of  IFN-~/on PECAM-1 expression in vivo may reflect 
among other things (0 functional changes in endothelial 
cells during in vitro culture, (it) functional differences asso- 
ciated with the tissue of  origin (i.e., normally avascular cor- 
nea versus the highly vascularized umbilical cord), or (iii) 
species differences. PECAM-1 contributes to the junctional 
integrity of  the vascular endothelium (51) and may have a 
role in neovascularization (52). It is interesting to speculate 
that the cornea may normally maintain its avascularity and 
discourage inflammatory responses by inhibiting PECAM-1 
expression on the endothelium of  peripheral vessels. IFN-~/ 
may overcome this inhibitory effect, and thus dramatically 
increase PECAM-1 expression. The increased PECAM-1 
expression may facilitate both neovascularization a d PMN 
extravasation i to the cornea. 
We demonstrate a good correlation between the degree 
of  PECAM-1 expression on corneal vascular endothelium 
and the number of  PMN in the perivascular space. More- 
over, PMN were consistently seen to accumulate in the 
lumen of corneal vessels after IFN-y  neutralization. This 
observation is consistent with the notion that the contin- 
ued high level of expression of ICAM-1 observed on the 
vascular endothelium of  these mice permits the [32 inte- 
grin-mediated firm adhesion of the PMN to the walls of  
the corneal vessels, whereas their transendothelial migration 
is blocked. Although correlative, our results strongly sug- 
gest that PECAM-1 is an important regulator of  PMN ex- 
travasation i  the chronically inflamed HSV-l- infected cor- 
nea. This is consistent with the observation that PECAM-1 
plays an important role in PMN extravasation at sites of 
acute inflammation (23-25). 
Evidence suggests that homophilic interaction ofPECAM-1 
on PMN and vascular endothelium is required for transen- 
dothelial migration (23). Our  observation that PMN 
within the blood vessels express readily detectable levels of  
PECAM-1 is consistent with the proposal put forth by other 
investigators (23) that a homophilic interaction of PECAM-1 
on the PMN and vascular endotheliurn may permit the 
PMN to pass through the endothelial junction in a zipper- 
like fashion. We also observed that PMN that extravasated 
into the cornea or into the peritoneal cavity lacked detect- 
able PECAM-1. We cannot currently rule out the possibil- 
ity that the apparent loss of PECAM-1 actually reflects the 
loss of  the particular epitope on PECAM-1 that is recog- 
nized by the anti--PECAM-1 mAb used in these studies. 
However, a more appealing interpretation would be that 
movement of  the PMN through the endothelial junction is 
facilitated by shedding of PECAM-1 from the surface of 
the PMN. Such a model would be consistent with the ob- 
servation ofBogen et al. (26) that CD31 is predominantly 
distributed on portions of  transmigrating lymphocytes that 
are in contact with or adjacent o areas of contact with en- 
dothelial cells. However, there is also published evidence 
that heterophilic interactions of PECAM-1 may facilitate 
migration of PMN through the vascular basement mem-  
brane (53, 54). Thus, it is not clear at what stage in the ex- 
travasation process PECAM-1 is lost from the surface of  
the PMN. 
We believe the cornea is an ideal tissue in which to study 
immunologically mediated inflammation. Its transparent 
nature permits in vivo monitoring of  many aspects of  the 
inflammatory process such as edema, leukocyte infiltration, 
and neovascularization. Moreover, its structural simplicity 
and absence of  confounding preexisting immunologic 
components make it easier to analyze inflammation histo- 
logically. In addition, HSV-1 corneal inflammation offers a 
reproducible model of  irnrnunologically mediated inflam- 
mation that is of  considerable clinical relevance. Therefore, 
we anticipate that the use of  this model will lead both to 
the elucidation of basic immunologic mechanisms that 
contribute to chronic inflammation and ultimately to im- 
proved treatment of this devastating ophthalmic disease. 
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